Ardelyx Inc. has raised $30 million in a series B preferred stock financing. The round included new investor Amgen Ventures and existing investors New Enterprise Associates, CMEA Capital and unnamed individual investors.
The company intends to use the proceeds to advance three products for constipation-predominant irritable bowel syndrome and preventing excess dietary sodium absorption, chronic kidney disease and type 2 diabetes. Ardelyx develops therapeutics acting in the gastrointestinal tract and devoid of systemic exposure.
Click here for the release from Market Wire.